Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Uso del sistema di impianto bioinduttivo REGENETEN™ in lesioni a spessore parziale di alto grado (IMPACT)

23 settembre 2026 aggiornato da: Smith & Nephew, Inc.

Valutazione della sicurezza e dell'efficacia di un impianto di collagene riassorbibile nel trattamento delle lacrime di spessore parziale di alto grado; Uno studio prospettico, multicentrico, randomizzato, di controllo (studio IMPACT)

The purpose of the study is to assess whether the REGENETEN™ Bioinductive Implant allows patients to get back to their everyday activities quicker than if the tendon is repaired by the standard repair technique 'Completion and Repair' for surgically treating partial-thickness rotator cuff tears.

Panoramica dello studio

Descrizione dettagliata

The primary objective of this study is to evaluate the functional recovery of patients with high grade (>50%) partial thickness tears at 3 months when treated with either Isolated Bioinductive Repair (IBR) or Completion and Repair (CAR).

Tipo di studio

Interventistico

Iscrizione (Stimato)

234

Fase

  • Non applicabile

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Contatto studio

Backup dei contatti dello studio

Luoghi di studio

    • Victoria
      • Richmond, Victoria, Australia, 3121
        • Reclutamento
        • OrthoSport Victoria
        • Investigatore principale:
          • Soong Chua
        • Contatto:
          • Haydn Klemm
    • Alberta
      • Calgary, Alberta, Canada, T2R 2G5
        • Reclutamento
        • Access Orthopaedics
        • Contatto:
          • Kristie More
        • Investigatore principale:
          • Ian Lo
    • Manitoba
      • Winnipeg, Manitoba, Canada
        • Attivo, non reclutante
        • Pan Am Clinic
    • Ontario
      • Hamilton, Ontario, Canada
        • Reclutamento
        • Research St. Joseph's
        • Investigatore principale:
          • Moin Khan
        • Contatto:
          • Danielle Dagher
      • Milan, Italia
        • Reclutamento
        • IRCCS Istituto Ortopedico Galeazzi,
        • Contatto:
          • Vincenzo Guarrella
        • Investigatore principale:
          • Ettore Taverna
      • Roma, Italia
        • Reclutamento
        • Fondazione Policlinico Universitario Campus Bio-Medico
        • Contatto:
          • Giuseppe Longo
        • Investigatore principale:
          • Giuseppe Longo
      • Bath, Regno Unito
        • Reclutamento
        • Sulis Hospital
        • Investigatore principale:
          • Andrew Chambler
      • Bristol, Regno Unito
        • Reclutamento
        • North Bristol NHS Trust
        • Contatto:
          • Steven Barnfield
        • Investigatore principale:
          • Iain Packham
      • Salford, Regno Unito, M6 8HD
        • Ritirato
        • Northern Care Alliance NHS Foundation Trust
    • Surrey
      • Chertsey, Surrey, Regno Unito, KT16 0PZ
        • Reclutamento
        • Ashford & St Peter's Hospitals NHS Foundation Trust
        • Investigatore principale:
          • Ali Narvani
        • Contatto:
          • Timnit Tekie
      • Madrid, Spagna, 28034
        • Reclutamento
        • Hospital Ramón y Cajal
        • Contatto:
          • Miguel Angel Ruiz Iban
        • Investigatore principale:
          • Miguel Angel Ruiz Iban
      • Madrid, Spagna, 28040
        • Reclutamento
        • Hospital Fundación Jiménez Díaz
        • Contatto:
          • Cristina Delgado del Cano
        • Investigatore principale:
          • Emilio Calvo
    • Georgia
      • Rome, Georgia, Stati Uniti, 30165
        • Reclutamento
        • Harbin Clinic
        • Investigatore principale:
          • Brandon Bushnell
        • Contatto:
          • Terri Brannon
    • Illinois
      • Rockford, Illinois, Stati Uniti, 61107
        • Reclutamento
        • OrthoIllinois LTD
        • Investigatore principale:
          • Scott Trenhaile
        • Contatto:
          • Catherine Ayala
    • Maryland
      • Baltimore, Maryland, Stati Uniti, 21215
        • Ritirato
        • Sinai Hospital Baltimore
    • Ohio
      • Garfield Heights, Ohio, Stati Uniti, 44125
        • Ritirato
        • Cleveland Clinic - Sports Health
    • Pennsylvania
      • Pittsburgh, Pennsylvania, Stati Uniti, 15213
        • Reclutamento
        • University of Pittsburgh
        • Investigatore principale:
          • Albert Lin
        • Contatto:
          • Alec Howard
    • Texas
      • Bedford, Texas, Stati Uniti, 76021
        • Attivo, non reclutante
        • Texas Orthopedic Specialists
      • The Woodlands, Texas, Stati Uniti, 77385
        • Ritirato
        • Houston Methodist The Woodlands
    • Wisconsin
      • Ashland, Wisconsin, Stati Uniti, 54806
        • Ritirato
        • Memorial Medical Center

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

18 anni e precedenti (Adulto, Adulto più anziano)

Accetta volontari sani

No

Sessi ammissibili allo studio

Tutto

Descrizione

Inclusion Criteria:

  • The subject must provide written informed consent.
  • Subject is > eighteen (18) years of age (no upper limit).
  • Subject has an isolated high-grade (>50% or >6mm) (Ellman grade III) partial thickness tear of supraspinatus or supraspinatus with infraspinatus.
  • Subject has failed a minimum of 3 months of conservative management for treatment of partial thickness rotator cuff tear.
  • Subject willing and able to make all required study visits.
  • Subject able to follow instructions and deemed capable of completing all study questionnaires.

Exclusion Criteria:

  • Subjects with insufficient tendon tissue quality for management and protection of the tendon injury using the isolated REGENETEN Bioinductive Implant system.
  • Subjects where the prescribed Physical Therapy guidelines stated in the protocol are not suitable for their rehabilitation.
  • Subjects with Samilson-Prieto osteoarthritis grade 2 and greater.
  • Subjects with current or prior infection of the ipsilateral shoulder.
  • Subjects with known hypersensitivity to bovine-derived materials.
  • Subjects with known inflammatory arthropathy, history of inflammatory arthropathy, chronic joint disease or chronic pain of upper extremities (shoulder(s), arm(s)).
  • Subjects with prior shoulder surgery on index shoulder, including subacromial decompression, biceps tenodesis/tenotomy, and acromioclavicular joint (ACJ) excision/distal clavicle excision (DCE).
  • Subjects with a planned surgery on the contra-lateral shoulder within the study period.
  • Systemic steroid use (oral, IV) or local steroid injection within 3 months of the date of surgery.
  • Subjects with a full thickness rotator cuff tear.
  • Subjects with a subscapularis tear requiring repair.
  • Subjects requiring a concomitant labral fixation procedure, concomitant surgery for bone defects requiring bone implantation or for superior labral tear from anterior to posterior (SLAP).
  • Subjects requiring a concomitant os acromiale fixation procedure.
  • Subjects with glenohumeral joint instability (multiple dislocations/subluxations).
  • Subjects with condition(s) that contraindicate or complicate outcomes of Isolated Bioinductive Repair or completion and repair e.g., > Hamada 3 rotator cuff arthropathy on X-ray, Goutallier atrophy > Grade 3, proximal humeral fracture or scapular fracture, avascular necrosis of the humeral head.
  • Subjects with neurologic conditions effecting either upper extremity.
  • Subjects who are unable to tolerate magnetic resonance imaging (MRI), due to psychiatric or medical contraindications.
  • Subjects who are pregnant or breast feeding.
  • Subjects who are currently involved in any injury litigation relating to the index shoulder.
  • Subjects with current workers compensation claim.
  • Subjects who are enrolled, or plan to enroll, in another clinical trial during this study that would affect the outcomes of this study.
  • Subjects with a history of poor compliance with medical treatment, physical therapy (PT)/rehabilitation, or clinical study participation.
  • Subject who, in the opinion of the Investigator, has an emotional or neurological condition that would pre-empt their ability or willingness to participate in the study including mental illness, mental retardation, and drug or alcohol abuse.
  • Subjects who do not meet the indication or are contraindicated according to specific Smith+Nephew REGENETEN System's Instructions for Use (IFUs).
  • Any subject that meets the definition of a Vulnerable Subject per ISO 14155 Section 3.55.
  • Subjects who have participated previously in this clinical trial and who have healed or been withdrawn
  • Subjects with a medical or physical condition that, in the opinion of the Investigator, would preclude safe subject participation in the study.

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Trattamento
  • Assegnazione: Randomizzato
  • Modello interventistico: Assegnazione parallela
  • Mascheramento: Separare

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Sperimentale: Isolated Bioinductive Repair

Surgical treatment of partial-thickness rotator cuff tears with the REGENETEN Bioinductive Implant system.

Isolated Bioinductive repair with REGENETEN™ Bioinductive Implant

Altri nomi:
  • Impianto bioinduttivo REGENETEN™
Comparatore attivo: Completion and Repair

Surgical treatment of partial-thickness rotator cuff tears using the standard surgical technique 'Completion and Repair'.

Standard surgical repair using the 'Completion and Repair' technique.

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Change in Western Ontario Rotator Cuff (WORC)
Lasso di tempo: Change from baseline to 3 months post-intervention

The WORC Index is self-administered, and includes a 5 different domains (physical symptoms, sports and recreation, work, social function, and emotions). Each question uses a visual analog scale (VAS) representing a 100-point scale ranging from 0 to 100. The maximum score is 2100 (worst possible symptoms). Zero (0) represents no symptoms at all. The final score can also be presented as a percentage by subtracting the total from 2100, dividing by 2100, and multiplying by 100. This will give you an overall percentage. The total final WORC Index scores can, therefore, range from 0% (lowest functional status level) to 100% (highest functional status level).

Change from baseline to 3 months post-intervention

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Western Ontario Rotator Cuff (WORC)
Lasso di tempo: Pre-op, 6 weeks, 3, 6, 12 and 24 months

The WORC Index is self-administered, and includes a 5 different domains (physical symptoms, sports and recreation, work, social function, and emotions). Each question uses a visual analog scale (VAS) representing a 100-point scale ranging from 0 to 100. The maximum score is 2100 (worst possible symptoms). Zero (0) represents no symptoms at all. The final score can also be presented as a percentage by subtracting the total from 2100, dividing by 2100, and multiplying by 100. This will give you an overall percentage. The total final WORC Index scores can, therefore, range from 0% (lowest functional status level) to 100% (highest functional status level).

Pre-op, 6 weeks, 3, 6, 12 and 24 months
Constant-Murley Score
Lasso di tempo: Pre-Op, 3, 6, 12 and 24 months

The Constant-Murley Score is a validated assessment of pain and shoulder functionality. The Constant Score is divided into 4 subscales: pain (15 points; VAS score range of 0-15), activities of daily living (20 points; range 0=worst, 5=best), strength (25 points; 1 point given per 0.5 kg of weights raised), and range of motion - forward flexion, external rotation, abduction and internal rotation of the shoulder (40 points; range 0=worst, 10=best). The higher the score, the higher the quality of function.

Pre-Op, 3, 6, 12 and 24 months
Subjective Shoulder Value (SSV) score
Lasso di tempo: Pre-Op, 6 weeks, 3, 12 and 24 months

The SSV is defined as a patient's subjective shoulder assessment expressed as a percentage of an entirely normal shoulder, which would score 100% (0% to 100% scale with 100% being normal).

Pre-Op, 6 weeks, 3, 12 and 24 months
EuroQol 5 Dimension 5 Level (EQ-5D-5L) VAS & index scores
Lasso di tempo: Pre-Op, 3 and 6 weeks, 3, 6, 12 and 24 months

To assess the subject's health state. The EQ-5D-5L is composed of the EQ- 5D-5L descriptive system and the EQ Visual Analogue scale (EQ VAS).

The descriptive system comprises 5 dimensions (mobility, self care, usual activities, pain/discomfort, anxiety/depression). Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems, and extreme problems. Responses are coded as single-digit numbers expressing the severity level selected in each dimension. For instance, 'slight problems' (e.g. 'I have slight problems in walking about') is always coded as '2'. The digits for the five dimensions are combined in a 5-digit code. The EQ- 5D-5L index value is derived by using the vendor supplied calculator to convert each 5-digit EQ- 5D-5L profile.

The EQ VAS corresponds to a 20 cm vertical, visual analogue scale ranging from 'the best health you can imagine' to 'the worst health you can imagine'.

A higher number is a better outcome.

Pre-Op, 3 and 6 weeks, 3, 6, 12 and 24 months
Change in Western Ontario Rotator Cuff (WORC)
Lasso di tempo: Change from Pre-op to 6 weeks, 3, 6, 12 and 24 months

The WORC Index is self-administered, and includes a 5 different domains (physical symptoms, sports and recreation, work, social function, and emotions). Each question uses a visual analog scale (VAS) representing a 100-point scale ranging from 0 to 100. The maximum score is 2100 (worst possible symptoms). Zero (0) represents no symptoms at all. The final score can also be presented as a percentage by subtracting the total from 2100, dividing by 2100, and multiplying by 100. This will give you an overall percentage. The total final WORC Index scores can, therefore, range from 0% (lowest functional status level) to 100% (highest functional status level).

Change from Pre-op to 6 weeks, 3, 6, 12 and 24 months
Change in Constant-Murley Score
Lasso di tempo: Change from Pre-Op to 6 weeks, 3, 12 and 24 months

The Constant-Murley Score is a validated assessment of pain and shoulder functionality. The Constant Score is divided into 4 subscales: pain (15 points; VAS score range of 0-15), activities of daily living (20 points; range 0=worst, 5=best), strength (25 points; 1 point given per 0.5 kg of weights raised), and range of motion - forward flexion, external rotation, abduction and internal rotation of the shoulder (40 points; range 0=worst, 10=best). The higher the score, the higher the quality of function.

Change from Pre-Op to 6 weeks, 3, 12 and 24 months
Change in Subjective Shoulder Value (SSV) score
Lasso di tempo: Change from Pre-Op to 6 weeks, 3, 12 and 24 months

The SSV is defined as a patient's subjective shoulder assessment expressed as a percentage of an entirely normal shoulder, which would score 100% (0% to 100% scale with 100% being normal).

Change from Pre-Op to 6 weeks, 3, 12 and 24 months
Percent Achieving Minimal Clinically Important Difference (MCID) for Constant-Murley Score
Lasso di tempo: Pre-Op, 3, 6, 12 and 24 months

The Constant-Murley Score is a validated assessment of pain and shoulder functionality. The Constant Score is divided into 4 subscales: pain (15 points; VAS score range of 0-15), activities of daily living (20 points; range 0=worst, 5=best), strength (25 points; 1 point given per 0.5 kg of weights raised), and range of motion - forward flexion, external rotation, abduction and internal rotation of the shoulder (40 points; range 0=worst, 10=best). The higher the score, the higher the quality of function.

Pre-Op, 3, 6, 12 and 24 months
Percent Achieving MCID for Western Ontario Rotator Cuff (WORC)
Lasso di tempo: Pre-op, 6 weeks, 3, 6, 12 and 24 months

The WORC Index is self-administered, and includes a 5 different domains (physical symptoms, sports and recreation, work, social function, and emotions). Each question uses a visual analog scale (VAS) representing a 100-point scale ranging from 0 to 100. The maximum score is 2100 (worst possible symptoms). Zero (0) represents no symptoms at all. The final score can also be presented as a percentage by subtracting the total from 2100, dividing by 2100, and multiplying by 100. This will give you an overall percentage. The total final WORC Index scores can, therefore, range from 0% (lowest functional status level) to 100% (highest functional status level).

Pre-op, 6 weeks, 3, 6, 12 and 24 months
Percent Achieving MCID for Subjective Shoulder Value (SSV) score
Lasso di tempo: Pre-Op, 6 weeks, 3, 12 and 24 months

The SSV is defined as a patient's subjective shoulder assessment expressed as a percentage of an entirely normal shoulder, which would score 100% (0% to 100% scale with 100% being normal).

Pre-Op, 6 weeks, 3, 12 and 24 months
Patient Satisfaction
Lasso di tempo: 6 weeks, 3, 6, 12 and 24 months

Comprise of 2 questions:

  1. Overall, I am satisfied with the outcome of my surgery
  2. I would recommend the procedure to a friend.

Question rated by the patient with Strongly Agree, Agree, Neither Agree nor Disagree, Disagree, Strongly Disagree.

6 weeks, 3, 6, 12 and 24 months
Pain, Visual analog scale (VAS) Score
Lasso di tempo: Pre-Op, 3 and 6 weeks, 3, 12 and 24 months

Pain is assessed on a 100-point scale ranging from 0 to 100, with zero (0) representing no pain and 100 representing the worst pain imaginable.

Pre-Op, 3 and 6 weeks, 3, 12 and 24 months
MRI Tendon Findings in subjects with Isolated Bioinductive Repair versus completion via Sugaya Score
Lasso di tempo: 12 months

The Sugaya score is classified into 5 categories: Type I to Type V. Type I indicates sufficient thickness with homogenously low intensity. Type II indicates sufficient thickness with partial high intensity. Type III indicates insufficient thickness without discontinuity. Type IV indicates presence of a minor discontinuity, suggesting a small full-thickness tear. Type V indicates the presence of a major discontinuity, suggesting a medium or large full-thickness tear.

12 months
MRI Tendon Findings in subjects with Isolated Bioinductive Repair versus completion via MRI assessment of percent filling
Lasso di tempo: 12 months

Percent tissue infil is graded at site of original tear and classified as 0% to < 25%, 25% to < 50%, 50% to < 75%, 75% to < 100% and 100%.

12 months
MRI Tendon Findings in subjects with Isolated Bioinductive Repair versus completion via MRI assessment of the signal intensity pattern
Lasso di tempo: 12 months

The Signal Intensity Pattern will be graded into 3 categories. Type I: Heterogeneous high signal intensity with fluid-like bright foci, Type II: Heterogeneous high signal intensity without fluid-like bright foci, Type III: Heterogeneous or homogeneous low signal intensity.

12 months
MRI Tendon Findings in subjects with Isolated Bioinductive Repair versus completion via Rotator cuff tendon thickness
Lasso di tempo: 12 months

Tendon thickness will be measured in millimeters (mm).

12 months
MRI Tendon Findings in subjects with Isolated Bioinductive Repair versus completion via Goutallier classification
Lasso di tempo: 12 months

The Goutallier classification will be used to classify the fatty infiltration of the rotator cuff. The Goutallier classification ranges from a grade of 0 indicating a completely normal muscles without any fatty streaks to a grade of 4 which indicates that more fat than muscle is present.

12 months
Incidence of Revision Surgery
Lasso di tempo: 1, 3 and 6 weeks, 3, 6, 12 and 24 months

Number of subjects requiring revision surgery

1, 3 and 6 weeks, 3, 6, 12 and 24 months
Time to return to work
Lasso di tempo: Up to 24 months

Number of weeks taken to return to work following surgery

Up to 24 months
Time to return to driving
Lasso di tempo: Up to 24 months

Number of weeks taken to return to driving following surgery

Up to 24 months
Time to return to sports
Lasso di tempo: Up to 24 months

Number of weeks taken to return to sport following surgery

Up to 24 months
Total operative time
Lasso di tempo: Inter-operative time

Time expressed in minutes

Inter-operative time
Physical Therapy Utilization
Lasso di tempo: Up to 24 months

Number visits following index surgery

Up to 24 months
Cumulative days of opioid use
Lasso di tempo: Day 1-14

Self-reported opioid use diary completed by the patient on a daily basis, from day 0-14, documenting opioid use. Consumption daily (YES/NO) x14 days, 'Have you taken any opioid medication today for shoulder pain?'

Day 1-14
Duration of shoulder immobilization following index surgery
Lasso di tempo: 1, 3 and 6 weeks, 3 months

Number of days

1, 3 and 6 weeks, 3 months

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Investigatori

  • Cattedra di studio: Laura Mills, Smith & Nephew, Inc.

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Effettivo)

30 agosto 2022

Completamento primario (Stimato)

15 aprile 2027

Completamento dello studio (Stimato)

28 febbraio 2029

Date di iscrizione allo studio

Primo inviato

29 giugno 2022

Primo inviato che soddisfa i criteri di controllo qualità

29 giugno 2022

Primo Inserito (Effettivo)

6 luglio 2022

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

28 settembre 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

23 settembre 2026

Ultimo verificato

1 settembre 2026

Maggiori informazioni

Termini relativi a questo studio

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

NO

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

No

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

Sì

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .

Sottoscrivi